–
Статьи в журналах
-
- 2025 Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
- Sangro Bruno, Kudo Masatoshi, Erinjeri Joseph P., Qin Shukui, Ren Zhenggang, Chan Stephen L., Arai Yasuaki, Heo Jeong, Mai Anh, Escobar Jose, Lopez Chuken Yamil Alonso, Yoon Jung-Hwan, Tak Won Young, Breder Valeriy V., Suttichaimongkol Tanita, Bouattour Mohamed, Lin Shi-Ming, Peron Jean-Marie, Nguyen Quang T., Yan Lunan, Chiu Chang-Fang, Santos Florinda A., Veluvolu Anil, Thungappa Satheesh Chiradoni, Matos Marco, Żotkiewicz Magdalena, Udoye Stephanie I., Kurland John F., Cohen Gordon J., Lencioni Riccardo
- в журнале The Lancet, издательство The Lancet Publishing Group (United Kingdom), том 405, № 10474, с. 216-232 DOI